Introduction
Gastric cancer is the world's second leading cause of cancer-related death. Unfortunately, most patients present with an advanced stage of disease, with a dismal outcome. Even after apparently curative resections, local recurrences or distant metastasis occur in up to 60% of the patients [1, 2] .
In this palliative situation patients do benefi t from combination chemotherapy compared to best supportive care, as it shows a modest survival benefi t, with improvement of quality of life [3] [4] [5] [6] . 5-Fluorouracil (5-FU) is still one of the main chemotherapeutic agents used in advanced gastric cancer, with a response rate (RR) as a single agent of 21% and a median survival of 6-7 months; while at the same time epirubicin, cisplatin, and 5-FU (ECF) is the most widely used combination regimen. With an overall RR of ECF of 40%-45% and a median survival of around 8-10 months it is considered a reference regimen, especially in Europe [2, [7] [8] [9] [10] . In the context of quality of life, the observed toxicity, prolonged hospital time (due to cisplatin infusion), and the risks of central venous access devices and ambulatory infusion pumps make the use of the combination regimens instead of monochemotherapy debatable. There is a need for an effective chemotherapy combination which is less toxic and can be easily administered in an outpatient setting. In order to improve convenience and tolerability three oral fl uoropyrimidines have been developed [11, 12] . One of them is UFT, a combination of tegafur, an oral prodrug of 5-FU which is slowly metabolized in the liver into the active drug 5-FU, and uracil, a competitive antagonist for dihydropyrimidine dehydrogenase (DPD), in a 1:4 M ratio. Uracil inhibits the degradation of 5-FU because it competes with 5-FU for DPD, leading to higher intratumoral 5-FU levels. This combination drug has an RR of about 16%-57% and a median overall survival (OS) of 5. 16 -54), a median time to progression of 4 months (95% CI, 0.5-7.5), and a median overall survival (OS) of 8 months (95% CI, 4.5-11.5). The 1-year survival rate was 26%. Three patients did not complete the fi rst course of 2 weeks; 1 died suddenly on day 16 with fatal lung embolism; 1 had rapid progressive disease and 1 experienced gastric hemorrhage on day 15 -both these patients withdrew. In the 20 patients assessable for toxicity no grade 4 toxicity occurred, grade 3 toxicity consisted of anemia in 1, diarrhea in 2, and neurotoxicity in 3 patients. No hand-foot syndrome (HFS) occurred. Conclusion. Oxaliplatin is an effective drug in gastric cancer, but, as previously reported, its feasibility in combination with capecitabine is hampered due to combined hand-foot-based toxicity. The present phase II study of a combination of oxaliplatin with UFT and leucovorin appears to have effi cacy and tolerability comparable to two other drug regimens used in gastric cancer, without the HFS problem.
Key words Metastatic gastric cancer · Chemotherapy · Handfoot syndrome · Outpatient setting is less toxic as far as myelosupression, stomatitis, diarrhea, and hand-foot syndrome (HFS) are concerned [11] [12] [13] [14] [15] [16] . Clinical studies in metastatic colon cancer have shown that UFT has an effi cacy profi le comparable to that of intravenous bolus administration of 5-FU [17, 18] . Capecitabine, the oral fl uoropyrimidine most often used worldwide, has a toxicity and effi cacy profi le similar to that of UFT, except that HFS, which is rarely observed with UFT, occurs in more than half of all patients treated with capecitabine [19, 20] . A third oral fl uoropyrimidine, S-1, has not been registered in Europe, and is licensed in Korea and Japan [11] .
Oxaliplatin is a third-generation platinum derivative that inhibits replication and transcription by the formation of DNA adducts. It has shown antitumor activity as monotherapy or in combination with 5-FU and leucovorin (LV) in various solid tumors, including gastric cancer. In comparison with cisplatin it has a more favorable toxicity profi le, with substantially lower rates of myelosuppression, nephrotoxicity, and ototoxicity, but with at least equivalent activity [21] [22] [23] [24] . The duration of intravenous hydration required with cisplatin use is not required for oxaliplatin, thereby facilitating outpatient administration. In combination with other chemotherapeutic agents, the UFT/LV schedules that are often used are UFT doses of 300-400 mg/m 2 per day, and LV doses of 25-500 mg, for 1-14 treatment days per 21 days or 1-28 treatment days per 35 days [11] . In combination with a fl uoropyrimidine, oxaliplatin is given in a 2-or 3-weekly schedule at an intravenous (i.v.) dose of, respectively, 85 or 130 mg/m 2 [25] [26] [27] . Based on these promising data of two different active agents with little overlap in terms of key side effects, we conducted a phase II study of oxaliplatin (130 mg/m 2 on day 1), UFT capsules (350 mg/m 2 per day), LV tablets (90 mg/day), every 8 h, for 14 days, in a 3-week cycle in patients with metastatic gastric cancer, in an outpatient setting, to investigate the antitumor activity and toxicity of this combination regimen.
Patients and methods

Eligibility
Between February 2004 and September 2008, patients with histologically confi rmed metastatic gastric cancer with at least one measurable lesion according to the response evaluation criteria in solid tumors (RECIST) were considered to be eligible in this open, noncomparative phase II study.
All patients were aged more than 18 years, with an ambulatory performance status of 0-1 on the Eastern Cooperative Oncology Group (ECOG) scale and a life expectancy of more than 3 months. Laboratory acceptance parameters included adequate hematological (white blood cell count 4.0 × 10 9 /l), hepatic (serum bilirubin < 1.5 × upper limit of normal), and renal (calculated creatinine clearance of >50 ml/min) function. Exclusion criteria consisted of: bone metastasis or effusions as the only manifestation of disease; clinical signs of brain metastasis; concurrent radiation therapy or previous chemotherapy; previous or current malignancies at other sites; evidence of serious active infections; severe cardiac and/or pulmonary failure; and pregnant or lactating women.
The study was approved by the ethics review board of our hospital (METc 2004.016) and was carried out in accordance with the Declaration of Helsinki principles. Written informed consent was obtained from all patients at a 7-day interval after thorough information had been given about the study.
Pretreatment evaluation
Prestudy assessment consisted of full medical history, vital signs, and physical examination. Further investigations included hematological and blood chemistry testing, electrocardiogram, chest X-ray, and a computed tomography (CT) scan of the abdomen.
Treatment schedule
Oxaliplatin (130 mg/m 2 ) was administered by a 2-h i.v. infusion on day 1 followed by oral UFT capsules (350 mg/m 2 per day) and LV tablets (90 mg/day) taken simultaneously every 8 h from the evening of day 1 to the morning of day 15, followed by a 7-day treatmentfree interval in a 3-week cycle. After two and four cycles, patients with a tumor response or stable disease continued on chemotherapy, receiving a maximum of six cycles.
Dose modifi cation
In patients with nonhematological toxicity of grade 2 or greater, treatment was postponed until toxicity resolved to grade 1 or less; the next UFT dose was reduced by 25% in patients with grade 3-4 toxicity. With hematological toxicity of grade 2 or greater, treatment was withheld until the white blood cell count was 3.0 × 10 9 /l or greater and the platelet count was 100 × 10 9 /l or greater. The oxaliplatin dose was reduced by 25% in patients with persistent (≥14 days) paresthesia or temporary painful paresthesia or functional impairment. Treatment was discontinued in patients with grade 4 nonhematological toxicity or nonrecovery of persistent paresthesia, and in those with nonhematological toxicity of grade 1 or greater despite a 2-week delay.
Treatment response and toxicity
Tumor response was evaluated on a CT scan after cycles 2 and 4, and after the treatment was fi nished. The tumor responses were classifi ed according to the RECIST. All patients were examined on days 1 and 15 of each cycle for vital signs, including physical examination, ECOG performance status, and complete blood counts and biochemical tests. Toxicity was evaluated according to the National Cancer Institute Common Toxicity Criteria (NCI CTC), version 2.0.
Statistical analyses
For the determination of the number of patients required in a preliminary and follow-up trial of a new chemotherapeutic agent, Gehan's two-stage design was used [28] . We expected a response rate of 30% or greater. If no objective response was seen in the fi rst 12 patients, then the probability of a response rate of 30% or greater would be below 5% and no additional patients would be entered. If, in the fi rst 12 patients more than four responses occurred, 8 additional patients would therefore be required for the evaluability of response. With a dropout frequency of 10%, 23 patients had to be included to estimate the 95% confi dence interval (CI) for a true response rate with a maximum width of 38%.
Results
Patient characteristics
During the study period a total of 23 patients, 21 men, and two women, with a median age of 60 years (range, 39-69 years) were enrolled. Eighty percent of these patients had a performance score of up to 1 at the start of treatment. Most patients (21/23) had a metastatic disease at the time of diagnosis, while 2 patients developed metastatic disease after surgical resection of the primary tumor. The most common metastatic sites were liver, lung, bone, or peritoneum (83% of the patients), while 17% of the patients had only lymph node metastasis. Two or more metastatic sites occurred in 61% of the patients. At the evaluation in November 2009 all 23 patients had died.
Effi cacy and survival
Twenty of the 23 patients were assessable for toxicity, while the remaining 3 did not complete the fi rst course of 3 weeks. One patient died suddenly on day 16 with a clinical diagnosis of fatal lung embolism, and a second patient had rapid progression of pulmonary metastasis and withdrew. The third patient, who still had his primary tumor in situ, experienced a gastric hemorrhage on day 15 and withdrew. All effi cacy data are reported using the intention-to-treat patient population.
The overall RR was 35% (95% CI, 16-54); one patient had a complete remission, seven patients had a partial response, eight patients had stable disease, and four patients had progressive disease. The median time to progression was 4 months (95% CI, 0.5-7.5) and the median OS was 8 months (95% CI, 4.5-11.5); see Figs. 1 and 2. The 1-year survival rate was 26%. Three initially responding patients in this study received second-line chemotherapy. One patient progressed after 1.5 years and was treated with irinotecan because of disease progression; however, this treatment was without an objective response. The two other patients progressed, after 6 and 8 months, respectively, and were treated with the oral fl uoropyrimidine capecitabine; however, this treatment was also without an objective response.
Toxicity
The patients received a total number of 86 cycles (median, 3.5 cycles; range, 1-6 cycles). Nine patients received the maximum of 6 cycles. The most common reported toxicity was oxaliplatin-related sensory neuropathy, in 11 patients. Usually this was mild and reversible, with a need for dose reduction of oxaliplatin in only 3 patients. Other nonhematological toxicities consisted of diarrhea in 6 patients (2 with grade 3 toxicity), grade 1/2 nausea in 7 patients, and grade 1 weight loss in 5 patients. Hematological toxicities observed were grade 2 anemia in 1 patient and grade 2 thrombocytopenia in 8 patients, and grade 3 anemia in 1 patient. No grade 4 hematological or nonhematological toxicity was reported (Table 1) . Eventually, treatment-related reasons for discontinuation were: persistent thrombocytopenia after 2 weeks of postponing the next cycle in 3 patients (after cycles 3, 4, and 5, respectively), grade 3 diarrhea in 2 patients, with the need for hospitalization and clinical worsening in 1 patient and recurrent diarrhea after dose reduction in the previous cycle in the other patient. The gastric hemorrhage that occurred on day 15 may have been treatment-related. The fatal lung embolism that occurred in cycle one did not seem to be treatment-related. Treatment was also discontinued due to clinical tumor progression in four patients, and due to tumor progression on CT scan in three patients. After discontinuation because of prolonged thrombocytopenia, two patients continued off study on mono UFT/LV.
Discussion
There is currently no universal standard regimen for the treatment of advanced gastric cancer. With two drugs commonly used drug regimens often consist of a cisplatin and fl uorouracil combination. In a palliative situation this regimen is not very patient-friendly, as hospitalization is often required, as is the use of continuous intravenous infusion.
Compared with the overall RR in the literature, with ECF and epirubicin, oxaliplatin, capecitabin (EOX) regimens showing RRs of 38%-47% and a median survival of around 8-11 months, the results of our study, showing an overall RR of 35% and median OS of 8.0 months, are similar but on the lower boundary [2, [7] [8] [9] [10] . This may be due to the relatively large number of patients showing early progression in our study who could not complete the fi rst course. Our study also included patients with a relatively high stage of advanced disease, as 61% of the patients had two or more metastatic sites, compared with 36%-40% of the patients in the randomized ECF for advanced and locally advanced esophagogastric cancer 2 (REAL-2) study [7] . Based on the remaining 20 evaluable patients in the present study, our combination chemotherapy of oxaliplatin, UFT, and LV showed acceptable antitumor activity, with an RR of 40% and a median OS of 9 months, and could be safely administered on an outpatient basis.
Several phase II-III studies have already indicated that oxaliplatin-based doublets may represent an effective and well-tolerated treatment option, compared to cisplatin, for patients with advanced gastric cancer [7, [29] [30] [31] [32] . In a study by Cunningham [7] , oxaliplatin, compared to cisplatin, showed signifi cantly less grade 3/4 neutropenia, alopecia, and thromboembolism, with signifi cantly more grade 3/4 diarrhea and peripheral neuropathy. This prompted these authors to the conclusion that oxaliplatin could replace cisplatin. The results of a study by Al-Batran et al. [33] are consistent with the REAL-2 data that oxaliplatin is at least as effective as cisplatin in patients with advanced gastric cancer. The results of these two studies [7, 33] are comparable regarding neurotoxicity, and are comparable with the generally mild and reversible neurotoxicity observed in our study, in which all patients with grade 3 neurotoxicity could continue on treatment after dose reduction. As patients prefer oral to intravenous therapy provided that no more side effects occur and effi cacy is not compromised, UFT and LV are a logical alternative to intravenous 5-FU [15] . Different phase II studies have investigated the effi cacy of UFT with LV in combination with another agent [11, [34] [35] [36] . These effi cacy results are comparable with the RR of 35% and confi dence interval of 16%-54% in our study.
More often studies in patients with advanced gastric cancer use the oral fl uoropyrimidine capecitabine. The REAL-2 data and the study of Okines et al. showed at least similar effi cacy of intravenous fl uorouracil and the oral fl uoropyrimidine capecitabine [7, 37] . The all-grade HFS was high in all groups [ECF, 29.8%; epirubicin, cisplatin, capecitabin (ECX), 45.9%; epirubicin, oxaliplatin, 5-FU (EOF), 28.9%; EOX, 39.3%]. Moreover, in the patients receiving capecitabine with epirubicin and cisplatin, signifi cantly more grade 3/4 HFS was observed (grade 3/4; 10.3%) than in the ECF group (grade 3/4; 4.3%) [7] . Another recently published phase II study Hand-foot syndrome  ----Neuropathy  2  6  3  -Diarrhea  1  3  2  -Nausea  4  3  --Weight loss  5  ---Thrombocytopenia  -8  --Leukopenia  1  ---Anemia  1  1  1  -ASAT  2  1  --ALAT  2  3  --Bilirubin  ---- NCI-CTC, National Cancer Institute Common Toxicity Criteria; ASAT, aspartate aminotransferase; ALAT, alanine aminotransferase also emphasized the problem of HFS, which occurred in 39% of the patient population receiving capecitabine and oxaliplatin [32] . The problem of hand-foot-based toxicity interfering with quality of life in a palliative situation is disturbing. In our study, as in many other studies with UFT-based combinations, patients reported hardly any HFS (<0.01%). This observation forms the basis for replacing the oral fl uoropyrimidine capecitabine with UFT. The effi cacies of two-drug combinations with UFT are comparable with those of other capecitabinebased regimens, with reported overall RRs of 35%-49% and median OS rates of 6-11 months [2, 11, 30, 38] . For the future, new promising targeted biological agents, often combined with chemotherapeutic drugs, are being investigated. Although biological agents are seemingly less toxic, epidermal growth factor receptor (EGFR) inhibitors can cause severe paronychia, and more commonly, acneiform rash [39] . Based on the toxicity profi les of UFT and capecitabine, it seems to be more logical to combine UFT with these new targeted biologicals.
In conclusion, based on the REAL-2 data, oxaliplatin has an important place in the fi rst-line treatment of advanced gastric cancer [7] . However, the use of oxaliplatin in combination with capecitabine has led to an increasing number of patients with hand-foot problems. Therefore, combining a UFT/LV-based regimen with oxaliplatin in patients with advanced gastric cancer has the advantage of a good tolerability profi le, with no HFS, and the regimen can be easily administered in an outpatient setting. For future studies with the new targeted agents, a combination of such agents with UFT would seem to be superior in dealing with the problem of hand-foot toxicity.
